The Author (JM) is an investigative writer and strategic thinker, and is renowned for being inquisitive and persistent. He has been intensively trained to maintain a cool, level-headed and analytical focus under extreme conditions. With almost 10 years of supreme low flying in the Canadian and Dutch Air Forces, JM has learned all about managing risk in the most demanding of circumstances; experience which he has put to good use following his decision to set his sights on a career in healthcare asset management.
After settling down on Wall Street, JM received his Series 7 and Series 9/10 securities license, and specialised in equity & options trading. He has experienced all financial crashes and crises of the 80s, 90s and 2000s at close quarters, and for more than 30 years lived and breathed the brokerage, investment banking and asset management industry.
During the 90s and 2000s, JM specialised in the pharmaceutical and biotechnology industries. His strength is early detection of major trends and shifts in drug development and pharma strategies. JM is recognised for his broad scientific insight and in-depth knowledge about human antibodies, oncology and autoimmune disease.
In June 2000, JM set up and ran a deep-focus private equity firm with a close friend and business partner (an MD and C-level pharma executive). Together, they operated with two high quality advisory boards and established a strong venture capital network. In 2011, they sold the PE company and have since managed a buy-out of the firm’s main asset.
The Key to Success
JM regularly brainstorms with long-term friends and experts in business (Big Pharma, Big Biotech and Venture Capital), in basic research (National Cancer Institute) and in clinical research (oncologists, immunologists, anaesthesiologists, dermatologists, respiratory & lung specialists). He is an avid reader with a strong will, an uncompromising nature and unbending personality.Disclaimer: BLOGBU$TER is about investigative journalism and not about recommendations to trade equity. It’s about narratives meant to provide foresight into the discreet world of biotech and finance. Action in reliance upon the info is strictly at your own risk and the Author may be biased; he’s the beneficial owner of ~12,000 shares of Genmab. Stock markets are inherently irrational and may act adversely. Moreover, new scientific discoveries may–at any time–derail a perfectly good drug development program.